NEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, ...
Dose-dense, every-2-week adjuvant chemotherapy using doxorubicin/cyclophosphamide (AC; 60/600 mg/m 2 every 2 weeks × four cycles) followed by paclitaxel (175 mg/m 2 ...
The study covered in this summary was published on ResearchSquare.com as a preprint and has not yet been peer reviewed. Phase 3 studies will assess the combination of plinabulin 40 mg and ...
- The plinabulin + pegfilgrastim combination reduces the incidence of profound neutropenia (ANC 53 % vs. pegfilgrastim alone - The plinabulin + pegfilgrastim combination reduces the odds of having ...
Purpose: We conducted a pilot study of dose-dense epirubicin/cyclophosphamide (EC) × 6 → paclitaxel (P) × 6 with pegfilgrastim. A previous dose-dense trial of FEC (5-fluorouracil [5-FU]/EC) × 6 with ...
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage global biopharmaceutical company focused on developing innovative ...
Neulasta (pegfilgrastim) is a brand-name drug that’s prescribed to treat radiation sickness and prevent certain complications of chemotherapy. Neulasta comes as an injectable solution. The dosage can ...
HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with a primary focus in hematology and oncology, announced today that the company submitted ...
Accuracy of Helical Computed Tomography and [18F] Fluorodeoxyglucose Positron Emission Tomography for Identifying Lymph Node Mediastinal Metastases in Potentially Resectable Non–Small-Cell Lung Cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback